Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors

被引：0
作者：
Daphne Day
Aaron R. Hansen
机构：
[1] Princess Margaret Cancer Centre,Bras Drug Development Program, Division of Medical Oncology and Hematology
[2] University of Toronto,Department of Medicine
[3] Ontario Institute for Cancer Research,OICR Research Fellow
来源：
BioDrugs | 2016年 / 30卷
关键词：
Melanoma; Renal Cell Carcinoma; Sunitinib; Ipilimumab; Pazopanib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Immune checkpoint inhibitors (ICIs), including antibodies targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein-1 (PD-1), have shown durable treatment responses in multiple tumor types by enhancing antitumor immunity. However, removal of self-tolerance can induce autoimmunity and produce a unique immune-driven toxicity profile, termed immune-related adverse events (irAEs). As ICIs gain approval for a growing number of indications, it is imperative clinicians increase their knowledge of and ability to manage irAEs. This review examines the etiology, presentation, kinetics, and treatment of irAEs and aims to provide practical guidance for clinicians.
引用
收藏
页码：571 / 584
页数：13
相关论文
共 502 条
[1]  
Dunn GP(2002)Cancer immunoediting: from immunosurveillance to tumor escape Nat Immunol 3 991-998
[2]  
Bruce AT(2007)Immunostimulatory monoclonal antibodies for cancer therapy Nat Rev Cancer 7 95-106
[3]  
Ikeda H(2013)A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application Nat Immunol 14 1212-1218
[4]  
Old LJ(2010)Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 711-723
[5]  
Schreiber RD(2011)Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2517-2526
[6]  
Melero I(2012)Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2443-2454
[7]  
Hervas-Stubbs S(2013)Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 134-144
[8]  
Glennie M(2015)Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer J Clin Oncol 33 2004-2012
[9]  
Pardoll DM(2015)Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med 372 2521-2532
[10]  
Chen L(2015)Nivolumab and ipilimumab versus ipilimumab in untreated melanoma N Engl J Med 372 2006-2017
12345678910